Elegen is a biotechnology company developing cell-free technologies for the rapid production of high-quality synthetic DNA. Its ENFINIA platform combines microfluidics, AI, robotics, and patented cell-free production methods to create long, complex, clonal-quality DNA without conventional cloning. This approach is designed to reduce the need for colony screening and additional sequencing, helping researchers move from sequence to usable material more quickly.

Elegen offers ENFINIA Linear DNA and ENFINIA IVT Ready DNA, including templates for mRNA workflows. Products can be up to 7 kb, are next-generation sequencing verified, and are manufactured in the United States for global shipment. The company states that ENFINIA DNA is typically delivered in 6–8 business days, with accuracy as high as 99.999% per base.

Elegen’s products support research and development in areas such as cell and gene therapy, genome editing, mRNA prophylactic and personalized cancer vaccines, and protein expression. The company also provides technical resources, including case studies, literature, videos, webinars, and customer support.